Abdominal Symptoms Assessed With the CFAbd-Score are Associated With Intestinal Inflammation in Patients With Cystic Fibrosis.
Anke Jaudszus, Elena Pfeifer, Michael Lorenz...
https://pubmed.ncbi.nlm.nih.gov/34789668/Actively Recruiting
Led by Medizinische Hochschule Brandenburg Theodor Fontane · Updated on 2023-04-04
2000
Participants Needed
2
Research Sites
52 weeks
Total Duration
This research aims to develop, validate, and evaluate a new questionnaire called the CFAbd-Score to assess and measure abdominal symptoms in patients with cystic fibrosis, a genetic disease affecting multiple organs and shortening life expectancy. The study follows FDA guidelines to create patient-reported outcome measures PROMs specifically for cystic fibrosis and includes patients, their families, and healthcare professionals across different countries. The goal is to better understand abdominal involvement in cystic fibrosis and improve symptom tracking. The study involves developing a multimodal questionnaire assessing abdominal symptoms, evaluating its reliability, reproducibility, and responsiveness by comparing results between cystic fibrosis patients and age-matched healthy controls. It also includes creating related tools a daily symptom diary for patients and a version for children under 12 years old. The questionnaire will be adapted and tested in multiple countries and languages, with assessments of its relationship to clinical markers and ultrasound findings. Participants will complete the CFAbd-Score questionnaire and related diaries over a period of up to 7 years. The study will collect data on abdominal symptoms, genotype, clinical history, and laboratory results. The research team will monitor symptom patterns and evaluate changes related to new therapies. Healthy volunteers matched by age will also participate to provide comparison data. This long-term observational study will help refine symptom measurement tools and improve abdominal symptom assessment in cystic fibrosis care.
CONDITIONS
Development and Validation of a Disease Specific PROM to Assess Abdominal Involvement in Patients With CF (CFAbd-Score)
J
Jochen G Mainz, Prof. MD
F
Franziska Duckstein, MA
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medizinische Hochschule Brandenburg Theodor Fontane
Lead Sponsor
University of Jena
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - Up to 7 years
Participants complete questionnaires to identify and quantify abdominal symptoms related to cystic fibrosis following FDA guidelines for patient-reported outcome measures (PROM).
Multiple questionnaire assessments over the study period
Duration - Up to 7 years
Participants are observed over time to assess abdominal symptoms, their relation to clinical findings, and response to therapies through repeated questionnaire assessments.
Ongoing assessments throughout the study duration
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Anke Jaudszus, Elena Pfeifer, Michael Lorenz...
https://pubmed.ncbi.nlm.nih.gov/34789668/Pauline Sadrieh, Lilith Bechinger, Franziska Duckstein...
https://pubmed.ncbi.nlm.nih.gov/40701924/Jochen G Mainz, Carlos Zagoya, Louise Polte...
https://pubmed.ncbi.nlm.nih.gov/35721187/Anke Jaudszus, Elisa Zeman, Tatjana Jans...
https://pubmed.ncbi.nlm.nih.gov/30887269/Harold Tabori, Anke Jaudszus, Christin Arnold...
https://pubmed.ncbi.nlm.nih.gov/29234058/L R Caley, C Zagoya, F Duckstein...
https://pubmed.ncbi.nlm.nih.gov/36710099/Harold Tabori, Christin Arnold, Anke Jaudszus...
https://pubmed.ncbi.nlm.nih.gov/28472055/Medizinische Hochschule Brandenburg Theodor Fontane
Lead Sponsor
University of Jena
Collaborating Sponsor